Three tests that can be used to profile the genetic makeup of breast cancer tumours and guide decisions on whether people will respond to chemotherapy have been approved for NHS use. The National ...
The diagnostics advisory committee considered evidence on tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node (LN)‑positive early breast cancer from several sources, ...
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...
PALO ALTO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Flatiron Health, a leading healthtech company dedicated to ...
UAB Pathology and the Division of Genomic Diagnostics and Bioinformatics are pleased to announce a new next-generation sequencing (NGS) comprehensive genomic profiling (CGP) Solid500 test which ...
GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...
A lipid profiling blood test may predict the risk for type 2 diabetes and CVD years in advance, according to findings published in PLOS Biology. “The lipidomic risk, which is derived from only one ...
The DNA sequencing giant Illumina has launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies. Built off of its ...
The company expands precision oncology portfolio with new Paletrra spatial proteomics platform "The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback